219 related articles for article (PubMed ID: 30416119)
1. [Development of a Therapeutic Drug for Narcolepsy].
Irukayama-Tomobe Y; Yanagisawa M
Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
3. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
4. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
5. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Ishikawa T; Hara H; Kawano A; Kimura H
Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
[TBL] [Abstract][Full Text] [Related]
7. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
[TBL] [Abstract][Full Text] [Related]
8. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
9. An overview of hypocretin based therapy in narcolepsy.
Takenoshita S; Sakai N; Chiba Y; Matsumura M; Yamaguchi M; Nishino S
Expert Opin Investig Drugs; 2018 Apr; 27(4):389-406. PubMed ID: 29623725
[TBL] [Abstract][Full Text] [Related]
10. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
11. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.
Black SW; Schwartz MD; Chen TM; Hoener MC; Kilduff TS
Biol Psychiatry; 2017 Nov; 82(9):623-633. PubMed ID: 27919403
[TBL] [Abstract][Full Text] [Related]
12. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia.
Mezeiova E; Janockova J; Konecny J; Kobrlova T; Benkova M; Dolezal R; Prchal L; Karasova-Zdarova J; Soukup O; Korabecny J
Bioorg Chem; 2020 Oct; 103():104179. PubMed ID: 32891860
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
14. The present and future of synthetic orexin receptor agonists.
Saitoh T; Sakurai T
Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
[TBL] [Abstract][Full Text] [Related]
15. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
Mieda M; Willie JT; Hara J; Sinton CM; Sakurai T; Yanagisawa M
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4649-54. PubMed ID: 15070772
[TBL] [Abstract][Full Text] [Related]
16. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
[TBL] [Abstract][Full Text] [Related]
17. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
[TBL] [Abstract][Full Text] [Related]
18. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
19. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.
Hasegawa E; Yanagisawa M; Sakurai T; Mieda M
J Clin Invest; 2014 Feb; 124(2):604-16. PubMed ID: 24382351
[TBL] [Abstract][Full Text] [Related]
20. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
